BiotechTube

YM150 + Placebo + Enoxaparin

Phase 2/3Completed
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Thromboembolism

Conditions

Venous Thromboembolism

Trial Timeline

May 1, 2009 → Jan 1, 2010

NCT ID
NCT00917254

About YM150 + Placebo + Enoxaparin

YM150 + Placebo + Enoxaparin is a phase 2/3 stage product being developed by Astellas Pharma for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00917254. Target conditions include Venous Thromboembolism.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (2)

NCT IDPhaseStatus
NCT00913120Phase 2/3Completed
NCT00917254Phase 2/3Completed

Competing Products

20 competing products in Venous Thromboembolism

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
52
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Standard of CareDaiichi SankyoPhase 3
77
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
52
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
77
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
77
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
77
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + enoxaparinAstellas PharmaPhase 2/3
65
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
23
dalteparin injectionEisaiPhase 3
77
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
33
Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + Xarelto (Rivaroxaban, BAY59-7939) + (LMW) Heparin + Vitamin K AntagonistJohnson & JohnsonPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85